Table 1: CD4 category by treatment regimens (reproduction of ASR report table specifically CD4 re categorisation of CD4) (a) (b) 2009.

Size: px

Start display at page:

Download "Table 1: CD4 category by treatment regimens (reproduction of ASR report table specifically CD4 re categorisation of CD4) (a) (b) 2009."

Deborah Russell
5 years ago
Views:

1 Request: Industry Date: January 2011 Purpose: The data will be used internally only to populate patient forecasting models which are used for business planning. Business planning includes stock requirements forecasts, revenues forecasts and developing a general understanding of the market. Table 1: CD4 category by treatment regimens (reproduction of ASR report table specifically CD4 re categorisation of CD4) (a) (b) (a) 2008 Rx NAIVE MONO/DUAL 3+ NNRTI+PI,+/ NRTI Regimen 3+ NRTI+/ PI,NO NNRTI 3+ NRTI+NNRTI, NO PI Total 1 N % N % N % N % N % < > Total Patients enrolled in AHOD and who had a visit follow up during 2008 (b) 2009 Rx NAIVE MONO/DUAL 3+ NNRTI+PI,+/ NRTI Regimen 3+ NRTI+/ PI,NO NNRTI 3+ NRTI+NNRTI, NO PI Total 2 N % N % N % N % N % < > Total Patients enrolled in AHOD and who had a follow up visit during Patient totals for 2009 are less than 2008 totals dues to a cohort site unable to provide follow up data in 2009 for a large proportion of its cohort.

2 Table 2: CD4 at the time of commencing antiretroviral treatment. CD4+ (cells/µl) Year < >500 Total 1 N % N % N % N % <= Total Patients need to have commenced their first antiretroviral treatment (ART) AFTER having enrolled in AHOD; and have a CD4 measure available 1 year prior to commencing ART.

3 Table 3: Top ART combinations (3+ ARVs), reproduction of Table 7 in AHOD Annual report for years (a) 2007, (b) 2008, (c) (a) (b) (c) Combination N % Cum % Combination N % Cum % Combination N % 1 TRUVADA EFAV TRUVADA NEV TRUVADA EFAV KIVEXA NEV TRUVADA EFAV TRUVADA NEV TRUVADA NEV KIVEXA NEV KIVEXA NEV ABC LAM NEV TRUVADA ATAZ RITON TRUVADA ATAZ RITON KIVEXA EFAV ABC LAM NEV KIVEXA EFAV CBV NEV KIVEXA EFAV ABC LAM NEV TRUVADA ATAZ RITON CBV NEV TRUVADA KALETRA CBV EFAV KIVEXA ATAZ RITON EMTRIC EFAV TENOF KIVEXA ATAZ RITON TRUVADA KALETRA CBV NEV TRUVADA KALETRA EMTRIC EFAV TENOF EMTRIC ATAZ RITON TENOF ABC LAM EFAV EMTRIC ATAZ RITON TENOF KIVEXA ATAZ RITON TRIZ TRUVADA RITON TRUVADA RITON LAM NEV TENOF CBV EFAV TRUVADA RALT LAM EFAV TENOF ABC LAM EFAV CBV EFAV ABC ATAZ RITON TENOF ABC ATAZ RITON TENOF KIVEXA ATAZ EMTRIC EFAV TENOF EMTRIC KALETRA TENOF TRIZ LAM ATAZ RITON TENOF TRIZ EMTRIC KALETRA TENOF LAM AZT NEV KIVEXA ATAZ ABC LAM ATAZ RITON TRUVADA RITON EMTRIC NEV TENOF EMTRIC NEV TENOF EMTRIC KALETRA TENOF LAM NEV TENOF ABC ATAZ RITON TENOF ABC LAM AZT ABC LAM ATAZ RITON ABC LAM EFAV LAM D4t NEV LAM ATAZ RITON TENOF LAM NEV TENOF LAM KALETRA TENOF KIVEXA KALETRA TRUVADA ATAZ ABC LAM ATAZ RITON LAM AZT NEV KIVEXA KALETRA ABC LAM RITON LAM EFAV TENOF LAM ATAZ RITON TENOF KIVEXA KALETRA LAM D4t NEV LAM D4t NEV KIVEXA ATAZ ABC LAM AZT ABC KALETRA TENOF Cum %

4 28 EMTRIC ATAZ RITON TENOF KIVEXA RITON KIVEXA ATAZ RITON TENOF ABC KALETRA TENOF TRUVADA ATAZ KIVEXA RITON EMTRIC NEV TENOF ABC LAM RITON LAM EFAV TENOF ABC LAM KALETRA ABC KALETRA TENOF KIVEXA RITON ABC LAM KALETRA LAM AZT EFAV unique ART regimens; and a total of 1,995 regimens recorded among 1,638 patients on combination ART unique ART regimens; and a total of 2,007 regimens recorded among 1,709 patients on combination ART unique ART regimens; and a total of 1,888 regimens recorded among 1,700 patients on combination ART. NOTE: Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir).

5 Table 4(a): Most frequent ARV combinations (3+ ARVs) in 2007 (A modified Table 7 from AHOD Annual report). 334 unique ART regimens; and a total of 1,995 regimens recorded among 1,638 patients on combination ART. NOTES: (1) Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir). (2) Some ARVs are masked with an X in order to reduce the total number of regimens and focus on the core components observed in AHOD. (3) Combinations with an X component are further described by whether the X s are from the NRTI class of drugs or Other (NNRTI, Fusion and Entry Inhibitors, Trial drug) or both NRTI and Other. (4) Combinations marked with a P indicate a Protease Inhibitor is used in the combination. (5) NRTI sparing is defined as a regimen without a NRTI component class drug. Combination ARV Count Cumulative count (%) Description of X NRTI Other NRTI + Other TRUVADA EFAV KIVEXA NEV TRUVADA NEV ABC NEV X KIVEXA EFAV TRUVADA ATAZ RITON CBV NEV ATAZ RITON TENOF X EFAV TENOF X NEV TENOF X NEV X KALETRA TENOF X CBV EFAV KIVEXA ATAZ RITON TRUVADA KALETRA ABC EFAV X TRIZ EFAV X ABC ATAZ RITON TENOF ABC ATAZ RITON X ABC RITON X P* ABC X TRUVADA RITON P* ABC KALETRA X KIVEXA KALETRA

6 KIVEXA ATAZ KALETRA X ABC ATAZ X TRUVADA ATAZ RITON X ABC KALETRA TENOF RITON DARUN TENOF X RITON TENOF X P NRTI SPARING N/A *Actual Protease Inhibitor (P) is currently unknown due to a systematic data reporting error at a select few sites. Issue is to be rectified at the source in the future.

7 Table 4(b): Most frequent ARV combinations (3+ ARVs) in 2008 (A modified Table 7 from AHOD Annual report). 355 unique ART regimens; and a total of 2,007 regimens recorded among 1,709 patients on combination ART. NOTES: (1) Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir). (2) Some ARVs are masked with an X in order to reduce the total number of regimens and focus on the core components observed in AHOD. (3) Combinations with an X component are further described by whether the X s are from the NRTI class of drugs or Other (NNRTI, Fusion and Entry Inhibitors, Trial Drug) or both NRTI and Other. (4) Combinations marked with a P indicate a Protease Inhibitor is used in the combination. (5) NRTI sparing is defined as a regimen without a NRTI component class drug. Combination ARV Count Cumulative count (%) Description of X NRTI Other NRTI + Other TRUVADA NEV TRUVADA EFAV KIVEXA NEV TRUVADA ATAZ RITON ABC NEV X KIVEXA EFAV ATAZ RITON TENOF X EFAV TENOF X NEV TENOF X CBV NEV KIVEXA ATAZ RITON TRUVADA KALETRA KALETRA TENOF X NEV X ABC EFAV X CBV EFAV TRUVADA RITON P* ABC ATAZ RITON TENOF TRIZ ABC ATAZ RITON X KIVEXA ATAZ EFAV X ABC KALETRA X ABC RITON X P* KIVEXA KALETRA

8 RITON DARUN TENOF X ABC X RITON DARUN RALT X TRUVADA ATAZ ABC ATAZ X KIVEXA RITON P* ABC KALETRA TENOF TRUVADA ATAZ RITON X NRTI SPARING N/A *Actual Protease Inhibitor (P) is currently unknown due to a systematic data reporting error at a select few sites. Issue is to be rectified at the source in the future.

9 Table 4(c): Most frequent ARV combinations (3+ ARVs) in 2009 (A modified Table 7 from AHOD Annual report). 347 unique ART regimens; and a total of 1,888 regimens recorded among 1,700 patients on combination ART. NOTES: (1) Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir). (2) Some ARVs are masked with an X in order to reduce the total number of regimens and focus on the core components observed in AHOD. (3) Combinations with an X component are further described by whether the X s are from the NRTI class of drugs or Other (NNRTI, Fusion and Entry Inhibitors, Trial drug) or both NRTI and Other. (4) Combinations marked with a P indicate a Protease Inhibitor is used in the combination. (5) NRTI sparing is defined as a regimen without a NRTI component class drug. Combination ARV Count Cumulative count (%) Description of X NRTI Other NRTI + Other TRUVADA EFAV TRUVADA NEV KIVEXA NEV TRUVADA ATAZ RITON KIVEXA EFAV ATAZ RITON TENOF X ABC NEV X EFAV TENOF X TRUVADA KALETRA CBV NEV NEV TENOF X KIVEXA ATAZ RITON KALETRA TENOF X RITON DARUN RALT X TRUVADA RALT TRUVADA RITON P NEV X CBV EFAV ABC ATAZ RITON X KIVEXA ATAZ TRIZ ABC EFAV X ABC ATAZ RITON TENOF RITON DARUN TENOF X KIVEXA KALETRA

10 TRUVADA ATAZ RITON DARUN TENOF RALT X TENOF RALT X KALETRA X KIVEXA ATAZ RITON TENOF NRTI SPARING N/A * Actual Protease Inhibitor (P) is currently unknown due to a systematic data reporting error at a select few sites. Issue is to be rectified at the source in the future.

Industry Data Request

Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,